At a glance
| Known as | ALKS 7290 |
|---|---|
| Sponsor | Alkermes |
| Mechanism | Orexin receptor agonist |
| Stage | Phase 1 |
| Indications | ADHD |
| Registered trials | 0 |
| Last verified | 4 Aug 2026 |
Where it stands
ALKS 7290 points the orexin mechanism at attention-deficit hyperactivity disorder. It is the furthest any programme in this class strays from sleep medicine, and the clearest sign that sponsors see orexin signalling as a lever on wakefulness and attention generally rather than on narcolepsy alone.
It sits at Phase 1 on Alkermes' own pipeline page and is not yet listed on ClinicalTrials.gov under this compound name.
ALKS 7290 — common questions
What is ALKS 7290 for?
Attention-deficit hyperactivity disorder, according to Alkermes' pipeline page.
What phase is ALKS 7290 in?
Phase 1. It is not yet listed on ClinicalTrials.gov under this compound name, so Alkermes' pipeline page is the only public source.
The rest of the class
Every other orexin agonist tracked here.
oveporexton
Takeda Pharmaceutical Company · Approved · NT1
alixorexton
Alkermes plc · Phase 3 · NT1 / NT2 / IH
cleminorexton
Centessa Pharmaceuticals · Phase 3 · NT1 / NT2 / IH
E2086
Eisai Co. · Phase 2 · NT1
TAK-360
Takeda Pharmaceutical Company · Phase 2 · NT1 / NT2 / IH
ALKS 4510
Alkermes plc · Phase 1 · Fatigue in MS / Fatigue in Parkinson's
BP-205
Harmony Biosciences Holdings · Phase 1 · Not yet specified
ORX142
Centessa Pharmaceuticals · Phase 1 · Neurological / Neurodegenerative
ORX489
Centessa Pharmaceuticals · Phase 1 · Neuropsychiatric
Source
This entry was last checked against its primary source on 4 Aug 2026 by Simon Stawski: https://www.alkermes.com/research-and-development/pipeline
Found something out of date? Send a correction with a primary source and it will be fixed.
Get told when this changes
One email when ALKS 7290 changes phase, reads out, or hits a regulatory milestone.
One email per real change. No tracking pixels, no list rental, one-click unsubscribe.